StockData
Palvella Therapeutics, Inc. logo

Palvella Therapeutics, Inc. (PVLA) stock

PVLANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$146.58+2.23 (+1.54%)

Close on Nov 18, 2026Market cap $2.11BP/E –Yield –

Palvella Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Palvella Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$57.74M. For fiscal 2025 it was -$38.60M. The highest annual figure on record is $553.83K in fiscal 2013.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$38.60M–
FY2024Dec 31, 2024-$14.10M–
FY2023Dec 31, 2023-$11.87M–
FY2022Dec 31, 2022-$43.47M–
FY2021Dec 31, 2021-$51.83M–
FY2020Dec 31, 2020-$33.92M–
FY2019Dec 31, 2019-$27.16M–
FY2018Dec 31, 2018-$30.83M–
FY2017Dec 31, 2017-$14.59M–
FY2016Dec 31, 2016-$22.76M–
FY2015Dec 31, 2015-$13.68M–
FY2014Dec 31, 2014-$7.20M-1399.7%
FY2013Dec 31, 2013$553.83K–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$21.41M–
Q1 FY2026Mar 31, 2026-$14.86M–
Q4 FY2025Dec 31, 2025-$11.30M–
Q3 FY2025Sep 30, 2025-$10.18M–
Q2 FY2025Jun 30, 2025-$9.25M–
Q1 FY2025Mar 31, 2025-$7.87M–
Q4 FY2024Dec 31, 2024-$4.37M-132.6%
Q3 FY2024Sep 30, 2024-$5.06M–
Q2 FY2024Jun 30, 2024-$2.91M-241.0%
Q1 FY2024Mar 31, 2024-$1.76M–
Q4 FY2023Dec 31, 2023$13.39M–
Q3 FY2023Sep 30, 2023-$11.81M–
Q2 FY2023Jun 30, 2023$2.06M–
Q1 FY2023Mar 31, 2023-$15.51M–
Q4 FY2022Dec 31, 2022-$11.52M–
Q3 FY2022Sep 30, 2022-$12.17M–
Q2 FY2022Jun 30, 2022-$12.33M–
Q1 FY2022Mar 31, 2022-$7.46M–
Q4 FY2021Dec 31, 2021-$11.00M–
Q3 FY2021Sep 30, 2021-$19.01M–
Q2 FY2021Jun 30, 2021-$16.76M–
Q1 FY2021Mar 31, 2021-$5.06M–
Q4 FY2020Dec 31, 2020-$12.41M–
Q3 FY2020Sep 30, 2020-$13.00M–
Q2 FY2020Jun 30, 2020-$4.66M–
Q1 FY2020Mar 31, 2020-$3.86M–
Q4 FY2019Dec 31, 2019-$1.33M–
Q3 FY2019Sep 30, 2019-$2.91M–
Q2 FY2019Jun 30, 2019-$12.23M–
Q1 FY2019Mar 31, 2019-$10.68M–
Q4 FY2018Dec 31, 2018-$12.65M-294.9%
Q3 FY2018Sep 30, 2018-$7.80M–
Q2 FY2018Jun 30, 2018-$2.24M–
Q1 FY2018Mar 31, 2018-$8.14M–
Q4 FY2017Dec 31, 2017$6.49M–
Q3 FY2017Sep 30, 2017-$5.18M–
Q2 FY2017Jun 30, 2017-$7.89M–
Q1 FY2017Mar 31, 2017-$8.01M–
Q4 FY2016Dec 31, 2016-$6.40M–
Q3 FY2016Sep 30, 2016-$6.18M–

More Palvella Therapeutics figures

See a number that looks wrong?